Table 2.
Laboratory parameters in moderately, severely and critically ill COVID-19 patients
| Baseline parameters | Moderately ill Patients | Severely ill patients | Critically ill patients | All patients | p value |
|---|---|---|---|---|---|
| (n = 11) | (n = 7) | (n = 6) | |||
| Hemoglobin (g/l) | 112.4 ± 16.63 | 104 ± 22.35 | 90.17 ± 37.73 | 102.6 ± 27.26 | 0.744 ANOVA |
| White blood cell (× 109/L) | 6.925 ± 2.842 | 7.92 ± 2.366 | 11.08 ± 4.304 | 8.5 ± 3.599 |
0.090 K-W |
| Neutrophil (× 109/L) | 4.462 ± 2.055 | 4.777 ± 3.417 | 9.537 ± 4.154 | 5.882 ± 3.712 | 0.012 ANOVA |
| Lymphocyte (× 109/L) | 1.571 ± 0.6184 | 1.634 ± 0.689 | 1.059 ± 0.5516 | 1.44 ± 0.6363 | 0.227 ANOVA |
| NLR | 3.825 ± 3.317 | 6.389 ± 9.717 | 10.82 ± 6.083 | 6.433 ± 6.501 |
0.065 K-W |
| Platelet (× 109/L) | 198.5 ± 41.79 | 231.2 ± 32.69 | 311 ± 156.9 | 224 ± 88.83 | 0.413 ANOVA |
| PLR | 171.8 ± 154.5 | 243.2 ± 251.9 | 226.9 ± 223.4 | 227.8 ± 195.8 |
0.208 K-W |
| Triglycerides (mmol/L) | 1.023 ± 0.2329 | 1.197 ± 0.2871 | 1.962 ± 1.081 | 1.408 ± 0.7893 | 0.080 ANOVA |
| ALT (U/L) | 18.86 ± 13.63 | 18 ± 15.75 | 36.67 ± 22.54 | 24.94 ± 18.84 | 0.168 ANOVA |
| D-Dimer (mg/l) | 0.92 ± 0.6479 | 2.07 ± 1.669 | 1.773 ± 0.7467 | 1.396 ± 0.924 | 0.744 ANOVA |
Abbreviations: NLR Neutrophil-to-lymphocyte ratio; PLR Platelet-to-lymphocyte ratio; ALT Alanine aminotransferase; ANOVA Analysis of variance; K-W Kruskall-Wallis